Date Added: 20/03/2017

Date Updated: 20/03/2017

Avacopan for ANCA-associated vasculitis – first and subsequent line

Specialties: Orthopaedics, rheumatology & podiatry

Technology Type: Drugs

Stage of development: Experimental - pilot or phase II

Stage of EAA: Prioritised for assessment

Description, patients and keywords:

TARGET GROUP

Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) – first and subsequent line.

TECHNOLOGY DESCRIPTION 

Avacopan (CCX-168) is a small molecule, complement C5a receptor inhibitor. Chemoattractant receptors, such as C5aR, are receptors for complement proteins involved in specific inflammatory responses. C5a is believed to be a potent chemoattractant underlying the inflammation-induced damage in certain autoimmune disorders, including AAV, thus inhibitors of C5aR have a therapeutic potential.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.